Live From Interphex in New York City - Updated

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Loading the player...

Following the completion of remediation efforts to deal with an FDA warning letter, Chris Phillips, AMRI's senior director of its Burlington, Massachusetts site, discusses what he considers to be a "new bar" in enforcement activity from the agency since 2009.

Phillips also discusses how AMRI voluntarily shut down its plant in Massachusetts following an FDA warning letter from August 2010.

"It's pretty evident across the industry...the new bar which has been set with regard to FDA compliance," Phillips said. He said his site was hit with a warning letter early on in this enforcement push, begun when FDA commissioner Margaret Hamburg took over. And now the company is able to pass on the lessons it's learned from that process to a number of its clients, he said.

New delivery technologies for poorly soluble compounds and how AMRI (Albany Molecular Research Institute) is looking to position itself in that market is another feature of this interview.

Related News

Burlington Re-inspection Earns AMRI New US FDA Form 483

Burlington Re-inspection Earns AMRI New US FDA Form 483

AMRI Stock Tumbles After Announcing B-MS Trial Ends

AMRI Stock Tumbles After Announcing B-MS Trial Ends

People - AMRI CEO Set to Retire; New President Catalent Asia

People - AMRI CEO Set to Retire; New President Catalent Asia

AMRI awarded nerve gas API development contract

UK Gov awards AMRI nerve agent countermeasure development contract

Regulatory thumbs-up as US FDA ends years of woe at AMRI's Burlington, MA facility

Close-out Letter a 'pivotal milestone' for AMRI's troubled Burlington plant

AMRI buys commercial manufacturer OsoBio for $110m

AMRI buys commercial manufacturer OsoBio for $110m

Sterile injectables returning in-house? Not so says AMRI who has entered the sector through the acquisition of CMO Oso Bio

Injectables outsourcing growing despite pharma M&A, says AMRI

AMRI buys two facilities from Aptuit in $60m deal

AMRI acquiring Aptuit assets, including UK aseptic site, in $60m deal

AMRI Deal a Catalyst for Pharma Growth says Codexis

AMRI Deal a Catalyst for Pharma Growth says Codexis

AMRI publish end-of-year results: contract manufacturing up

AMRI to Focus on Large Scale Manufacturing

AMRI has biggest supply contract renewed

AMRI has biggest supply contract renewed by GE Healthcare

AMRI to end operations at Hungary site by next Friday

AMRI to end operations at Hungary site by next Friday